Currently, there are five biologic TNFα inhibitors (TNFi; adalimumab, certolizumab pegol, etanercept, golilmumab, infliximab) which have been approved for clinical use, and the most common application is to treat RA and IBD [4]. This evidence concerns the gene TNF and inflammatory bowel disease.